Breast cancer drug Tykerb to be subsidised

Women suffering from a particularly aggressive form of breast cancer will have access to a new drug lapatinib (Tykerb) on the PBS that will improve quality of life and prolong some lives, reported by Australian Department of Health and Ageing.

From May 1, lapatinib (Tykerb) will be listed on the PBS. This is important news for people with advanced HER-2 positive breast cancer.

HER-2 positive breast cancer is an aggressive form of cancer that particularly impacts upon younger women. Around 87 per cent of patients diagnosed with advanced breast cancer will die from the disease within five years. About 2,000 Australians are diagnosed with HER-2 positive breast cancer each year.

Advanced HER-2 positive breast cancer is one that has spread to distant parts of the body (metastasised) or which cannot be removed with surgery'.

Breast cancer is the most common cancer in women and affects 14,000 Australians per year. In 2004, more than 2,600 people died from the disease in Australia.

Lapitinib has been found to slow the progress of and improve symptoms associated with advanced HER-2 positive breast cancer.

Without any subsidy, the medicine would cost women between $3,500 and $4,000 each month.

Lapatinib will be available to people with HER-2 positive metastatic or advanced breast cancer for whom other treatments have proved ineffective.


(Editor compiled and published Breast cancer drug Tykerb to be subsidised at HealthNewsTrack on April 8, 2008 sourced from Department of Health and Ageing - http://www.health.gov.au/)

Breast cancer - recent articles and current news stories:

- Whole genome breast cancer study launched by Mayo Clinic USA
- Long term hormone therapy linked to higher breast cancer risk
- Breast cancer risk gene can be discovered by massively parallel sequencing
- New technique for screening breast cancer using ultrasound
- Breast cancer funding restored by Komen Foundation to Planned Parenthood

Most related articles:

- Breast cancer drug Tykerb to be subsidised
- Tykerb with Herceptin increases advanced breast cancer survival - 7.6
- Breastfeeding mothers reduce breast cancer risk - 5
- Pregnancy hormone may prevent breast cancer - 4.9
- Breast cancer recurrence high in women with dense breasts - 4.9

More related articles:

- Breast cancer, Tykerb, Lapatinib, Health, Ageing, Cancer, Surgery
- Tykerb with Herceptin increases advanced breast cancer survival - 14.8
- 7% breast cancer patients have breast reconstruction surgery - 8.9
- Breast cancer recurrence high in women with dense breasts - 8.3
- Women with BRCA mutation most likely to undergo mastectomy - 6.9

Breast cancer related articles:

- Breastfeeding mothers reduce breast cancer risk - 5
- Breast cancer recurrence high in women with dense breasts - 4.9
- Exercise reduces breast cancer risk - 4.8
- 7% breast cancer patients have breast reconstruction surgery - 4.8

Breast cancer article/news source:

Read more health articles from Department of Health and Ageing and health articles from Australia.

Breast cancer - search related terms:

Ageing, Breast cancer, Cancer, Health, Lapatinib, Surgery, Tykerb,
Breast cancer books,

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
3.2